Cardiac Magnetic Resonance Imaging for Stage B Heart Failure

Heart Failure Clinics

Volumn 8, Issue 2, 2012, Pages 179-190

  Partington, Sara L ^a   Cheng, Susan ^a   Lima, João A C ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac MRI; Heart failure; Stage B heart failure

Indexed keywords

CATECHOLAMINE; CONTRAST MEDIUM; DOBUTAMINE; GADOLINIUM; GADOLINIUM PENTETATE; REGADENOSON;

CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM EXAMINATION; CHAGAS DISEASE; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; DIASTOLE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; EXERCISE TEST; HEART CYCLE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE QUALITY; INTERMETHOD COMPARISON; IONIZING RADIATION; ISCHEMIC CARDIOMYOPATHY; KIDNEY FAILURE; NEPHROGENIC SYSTEMIC FIBROSIS; NON INVASIVE PROCEDURE; NONISCHEMIC CARDIOMYOPATHY; OUTCOME ASSESSMENT; PHENOTYPE; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; RADIATION DOSE; REVIEW; SARCOIDOSIS; SYSTOLE; TISSUE CHARACTERIZATION; VELOCITY;

CARDIAC IMAGING TECHNIQUES; CARDIOMYOPATHIES; CARDIOMYOPATHY, HYPERTROPHIC; GADOLINIUM; HEART FAILURE; HUMANS; IMAGE ENHANCEMENT; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PROGNOSIS; RISK ASSESSMENT; SARCOIDOSIS; VENTRICULAR FUNCTION, LEFT;

EID: 84858157087     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.11.009     Document Type: Review

References (61)

1. Sechtem U., Mahrholdt H., Vogelsberg H. Cardiac magnetic resonance in myocardial disease. Heart 2007, 93:1520-1527.
2. Semelka R.C., Tomei E., Wagner S., et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J 1990, 119:1367-1373.
3. Daram S.R., Cortese C.M., Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005, 46:754-759.
4. Chrysochou C., Power A., Shurrab A.E., et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 2010, 5:484-489.
5. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243:148-157.
6. Broome D.R., Girguis M.S., Baron P.W., et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007, 188:586-592.
7. Wang T.J., Evans J.C., Benjamin E.J., et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003, 108:977-982.
8. Bellenger N.G., Burgess M.I., Ray S.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 2000, 21:1387-1396.
9. Teichholz L.E., Kreulen T., Herman M.V., et al. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976, 37:7-11.
10. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
11. Paelinck B.P., de Roos A., Bax J.J., et al. Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J Am Coll Cardiol 2005, 45:1109-1116.
12. Higgins C.B., Sovak M., Schmidt W., et al. Uptake of contrast materials by experimental acute myocardial infarctions: a preliminary report. Invest Radiol 1978, 13:337-339.
13. de Roos A., Doornbos J., van der Wall E.E., et al. MR imaging of acute myocardial infarction: value of Gd-DTPA. AJR Am J Roentgenol 1988, 150:531-534.
14. Lima J.A., Judd R.M., Bazille A., et al. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation 1995, 92:1117-1125.
15. Rochitte C.E., Lima J.A., Bluemke D.A., et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998, 98:1006-1014.
16. Simonetti O.P., Kim R.J., Fieno D.S., et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001, 218:215-223.
17. Sievers B., Elliott M.D., Hurwitz L.M., et al. Rapid detection of myocardial infarction by subsecond, free-breathing delayed contrast-enhancement cardiovascular magnetic resonance. Circulation 2007, 115:236-244.
18. Soriano C.J., Ridocci F., Estornell J., et al. Noninvasive diagnosis of coronary artery disease in patients with heart failure and systolic dysfunction of uncertain etiology, using late gadolinium-enhanced cardiovascular magnetic resonance. J Am Coll Cardiol 2005, 45:743-748.
19. Vogelsberg H., Mahrholdt H., Deluigi C.C., et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008, 51:1022-1030.
20. Rochitte C.E., Oliveira P.F., Andrade J.M., et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 2005, 46:1553-1558.
21. Karamitsos T.D., Francis J.M., Myerson S., et al. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol 2009, 54:1407-1424.
22. Patel M.R., Cawley P.J., Heitner J.F., et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009, 120:1969-1977.
23. Brittenham G.M. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011, 364:146-156.
24. Kirk P., Roughton M., Porter J.B., et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961-1968.
25. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006, 48:1977-1985.
26. Tsao C.W., Gona P., Salton C., et al. Subclinical and clinical correlates of left ventricular wall motion abnormalities in the community. Am J Cardiol 2011, 107:949-955.
27. Salerno M., Beller G.A. Noninvasive assessment of myocardial perfusion. Circ Cardiovasc Imaging 2009, 2:412-424.
28. Klem I., Heitner J.F., Shah D.J., et al. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol 2006, 47:1630-1638.
29. Wilke N., Jerosch-Herold M., Wang Y., et al. Myocardial perfusion reserve: assessment with multisection, quantitative, first-pass MR imaging. Radiology 1997, 204:373-384.
30. Gebker R., Jahnke C., Manka R., et al. Additional value of myocardial perfusion imaging during dobutamine stress magnetic resonance for the assessment of coronary artery disease. Circ Cardiovasc Imaging 2008, 1:122-130.
31. Bonow R.O. Identification of viable myocardium. Circulation 1996, 94:2674-2680.
32. Rahimtoola S.H. Hibernating myocardium has reduced blood flow at rest that increases with low-dose dobutamine. Circulation 1996, 94:3055-3061.
33. Wijns W., Vatner S.F., Camici P.G. Hibernating myocardium. N Engl J Med 1998, 339:173-181.
34. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002, 39:1151-1158.
35. Baer F.M., Theissen P., Schneider C.A., et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998, 31:1040-1048.
36. Wellnhofer E., Olariu A., Klein C., et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 2004, 109:2172-2174.
37. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100:1992-2002.
38. Ricciardi M.J., Wu E., Davidson C.J., et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001, 103:2780-2783.
39. Klein C., Nekolla S.G., Bengel F.M., et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002, 105:162-167.
40. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000, 343:1445-1453.
41. Rogers W.J., Kramer C.M., Geskin G., et al. Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. Circulation 1999, 99:744-750.
42. Aletras A.H., Tilak G.S., Natanzon A., et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 2006, 113:1865-1870.
43. Bart B.A., Shaw L.K., McCants C.B., et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997, 30:1002-1008.
44. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
45. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 51:e1-e62.
46. Wu K.C., Kim R.J., Bluemke D.A., et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998, 32:1756-1764.
47. Kwong R.Y., Chan A.K., Brown K.A., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006, 113:2733-2743.
48. Kwong R.Y., Sattar H., Wu H., et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008, 118:1011-1020.
49. Yan A.T., Shayne A.J., Brown K.A., et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 2006, 114:32-39.
50. Nazarian S., Bluemke D.A., Lardo A.C., et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 2005, 112:2821-2825.
51. Cheong B.Y., Muthupillai R., Wilson J.M., et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation 2009, 120:2069-2076.
52. Adabag A.S., Maron B.J., Appelbaum E., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
53. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
54. Ghio S., Revera M., Mori F., et al. Regional abnormalities of myocardial deformation in patients with hypertrophic cardiomyopathy: correlations with delayed enhancement in cardiac magnetic resonance. Eur J Heart Fail 2009, 11:952-957.
55. Maceira A.M., Prasad S.K., Hawkins P.N., et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008, 10:54.
56. Flett A.S., Hayward M.P., Ashworth M.T., et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010, 122:138-144.
57. Shehata M.L., Cheng S., Osman N.F., et al. Myocardial tissue tagging with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2009, 11:55.
58. Azevedo C.F., Cheng S., Lima J.A. Cardiac imaging to identify patients at risk for developing heart failure after myocardial infarction. Curr Heart Fail Rep 2005, 2:183-188.
59. Chung J., Abraszewski P., Yu X., et al. Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control. J Am Coll Cardiol 2006, 47:384-390.
60. Takeuchi M., Otsuji Y., Lang R.M. Evaluation of left ventricular function using left ventricular twist and torsion parameters. Curr Cardiol Rep 2009, 11:225-230.
61. Rosen B.D., Fernandes V.R., Nasir K., et al. Age, increased left ventricular mass, and lower regional myocardial perfusion are related to greater extent of myocardial dyssynchrony in asymptomatic individuals: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:859-866.